Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MPLT with free AI briefings, catalyst countdowns, and dilution alerts.

MPLT · MapLight Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$351.3M Cash on Hand
21.9mo Cash Runway
Follow MPLT by email Get an email when MPLT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MPLT, unsubscribe in one click. Privacy

📣 What MPLT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ML-004 (IR)/(ER) tablet Autism Spectrum Disorder Phase 2 · NCT05889273 Active not recruiting
ML-007C-MA Psychosis Associated With Alzheimer's Disease Phase 2 · NCT06887192 Recruiting
ML-007C-MA BID Schizophrenia Phase 2 · NCT07038876 Completed
ML-007C-MA QD Schizophrenia Phase 2 · NCT07038876 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MPLT holds $351.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $48M/quarter from operations, an estimated runway of 21.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MPLT files for a raise →

👥 Who Owns MPLT

Insiders 66.2% Other 5%+ holders 17.3% Institutions (143 holders) 16.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Catalyst4, Inc.
10% owner · +2.93M options
Insider 25,306,689 59.63% 2026-08-14
Forbion Growth Opportunities Fund III Co 5%+ holder (13G) 4,428,328 10.44% 2026-09-30
Nan Fung Group Holdings Limited 5%+ holder (13G) 2,915,874 6.87% 2026-08-13
Christopher A. Kroeger
Chief Executive Officer, Director · +93,955 options
Insider 1,297,099 3.06% 2026-10-15
Vishwas Setia
Chief Financial Officer
Insider 356,256 0.84% 2026-05-04
Erin Pennock Foff
Chief Medical Officer · +54,240 options
Insider 296,906 0.70% 2026-10-15
James Woodruff Lillie
Chief Scientific Officer · +31,395 options
Insider 198,597 0.47% 2026-10-15
Anatol Kreitzer
Chief Discovery Officer · +24,455 options
Insider 168,678 0.40% 2026-10-15
Jonathan Gillis
CAO and Interim CFO · +27,268 options
Insider 142,315 0.34% 2026-10-15
Kristopher Hanson
General Counsel · +31,395 options
Insider 128,024 0.30% 2026-10-15
Timothy John Garnett
Director · +14,902 options
Insider 67,581 0.16% 2026-06-23
Maria C Walker
Director · +14,902 options
Insider 62,703 0.15% 2026-06-23

Share count 42,436,326 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MPLT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MPLT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.